Analysis of public procurement for triple fixed-dose combinations in patients with COPD and bronchial asthma from 2020 to 2025
- 30 September 2025
- journal article
- Published by PANORAMA Publishing House
- No. 5,p. 64-70
Abstract
The article examines the dynamics of the Russian budget market for triple fixeddose combinations used in the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA) over the period from 2020 to 2025. It describes the main combinations available on the market. The analysis demonstrates a steady increase in sales volume and gradual growth in the share of new drugs. The study highlights the significance of these medications as universal tools in treating broncho-obstructive syndromes and identifies prospects for further expansion of their employment in clinical practice.Keywords
This publication has 3 references indexed in Scilit:
- Triple therapy in the treatment of patients with a combination of chronic obstructive pulmonary disease and bronchial asthmaPharmateca, 2024
- Clinical efficacy of a triple combination of budesonide/ glycopyrronium bromide/formoterol in the treatment of chronic obstructive pulmonary diseaseMeditsinskiy sovet = Medical Council, 2023
- Terapevt (General Physician)2020